SHANDONG XINHUA (00719) announced that the company has recently received the Drug Clinical Trial Approval Notice for LXH-1211 tablet issued by the National Medical Products Administration. According to the Drug Administration Law of the People's Republic of China and relevant regulations, after review, the clinical trial application for LXH-1211 tablet received on July 10, 2025, meets the requirements for drug registration, and approval is granted for conducting clinical trials for pulmonary arterial hypertension.

LXH-1211 tablet is a structurally novel compound designed specifically for the clinical manifestations and pathological essence of pulmonary arterial hypertension. Research shows that LXH-1211 has a dual mechanism of action: it can produce vasodilatory effects by stimulating soluble guanylate cyclase (sGC) to reduce pulmonary arterial hypertension, and it can also prevent vascular remodeling and fibrosis progression by inhibiting AMP-activated protein kinase (AMPK). The proposed clinical indication for this product is the treatment of pulmonary arterial hypertension.